Author: Vishnevskaya Karina
Translator: Uspanova Ainur
Copy editor: Kigbaeva Kamila
This study enrolled 1558 patients with advanced melanoma and known BRAF tumor status. All of them received pembrolizumab, and some of them were previously treated with BRAF inhibitors with or without MEK inhibitors.
Patients received pembrolizumab at doses of 2 mg / kg every 3 weeks, 10 mg / kg every 2 weeks, or 10 mg / kg every 3 weeks. The scientists set a goal: to assess the relationship between the status of wild-type BRAF or BRAF V600E / K-mutant and an inhibitor. This study was a pooled data subgroup analysis of three multinational, multisite studies.
The results of this study support the efficacy of pembrolizumab for the treatment of progressive melanoma, regardless of mutation status (BRAF V600E / K or prior BRAF inhibitor with or without MEK inhibitor therapy).
Source: https://jamanetwork.com/journals/jamaoncology/fullarticle/2768018
